Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:54:16.312Z.
Calculation as of: 2026-10-06T19:54:16.312Z.
Quote observation: 2026-10-06T19:50:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8daa83f2db5fafa0746e2d75675d68491b64c400a2027f88c30977eae97731f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$348.51M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.82M
EV/FCF Ratio
N/A
TTM Avg
50.02x
3Y Avg
37.43x
5Y Avg
35.40x
Market Cap
$355.36M
EV/FCF Ratio
12.19x
TTM Avg
33.56x
3Y Avg
51.03x
5Y Avg
195.24x
Market Cap
$359.88M
EV/FCF Ratio
N/A
TTM Avg
6.23x
3Y Avg
6.23x
5Y Avg
6.23x
Market Cap
$359.28M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $354.48M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $348.51M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.02M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $349.74M | 9.94x | 9.65x | 69.46x | 48.92x |
| Ocugen, Inc. (OCGN)vs › | $352.91M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.82M | N/A | 50.02x | 37.43x | 35.40x |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 12.19x | 33.56x | 51.03x | 195.24x |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.88M | N/A | 6.23x | 6.23x | 6.23x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $359.28M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.82M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
